TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2314-2321

  De Meyer, Sandra ^a   Azijn, Hilde ^a   Surleraux, Dominique ^a   Jochmans, Dirk ^a   Tahri, Abdellah ^a   Pauwels, Rudi ^a   Wigerinck, Piet ^a   De Béthune, Marie Pierre ^a  

^a Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; SITE DIRECTED MUTAGENESIS; VIRUS ISOLATION; VIRUS RECOMBINANT;

CELL LINE; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; RECOMBINATION, GENETIC; SULFONAMIDES;

EID: 19544386471     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2314-2321.2005     Document Type: Article

References (29)

1. Balotta, C., G. Facchi, M. Violin, S. Van Dooren, A. Cozzi-Lepri, F. Forbici, A. Bertoli, C. Riva, D. Senese, P. Caramello, G. Carnevale, G. Rizzardini, L. Cremonini, L. Monno, G. Rezza, C. F. Perno, G. Ippolito, A. d'Arminio-Monforte, A. M. Vandamme, and M. Moroni. 2001. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir. Immune Defic. Syndr. 27:499-505.
2. Bartlett, J. A., R. DeMasi, J. Quinn, C. Moxham, and F. Rousseau. 2001. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15:1369-1377.
3. Bilello, J. A, P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
4. Bilello, J. A., and G. L. Drusano. 1996. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J. Infect. Dis. 173:1524-1526.
5. Craig, J. C., I. B. Duncan, D. Hockley, C. Grief, N. A. Roberts, and J. S. Mills. 1991. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 16:295-305.
6. d'Arminio, M. A., A. C. Lepri, G. Rezza, P. Pezzotti, A. Antinori, A. N. Phillips, G. Angarano, V. Colangeli, A. De Luca, G. Ippolito, L. Caggese, F. Soscia, G. Filice, F. Gritti, P. Narciso, U. Tirelli, M. Moroni, et al. 2000. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 14:499-507.
7. Delwart, E. L., E. G. Shpaer, J. Louwagie, F. E. McCutchan, M. Grez, H. Rubsamen-Waigmann, and J. I. Mullins. 1993. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262:1257-1261.
8. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1997. DAIDS Virology Manual for HIV Laboratories. Publication NIH-97-3828. U.S. Department of Health and Human Services, Washington, D.C.
9. Fields, R. D., and M. V. Lancaster. 1993. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am. Biotechnol. Lab. 11:48-50.
10. Ghosh, A. K., J. F. Kincaid, W. Cho, D. E. Walters, K. Krishnan, K. A. Hussain, Y. Koo, H. Cho, C. Rudall, L. Holland, and J. Buthod. 1998. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 8:687-690.
11. Greco, W. R., G. Bravo, J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
12. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133:35-39.
13. Hertogs, K., M. P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peelers, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transciptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
14. Johnson, V. A., F. Brun-Vézinet, B. Clotet, B. Conway, R. D'Aquila, L. Demeter, D. Kuritzkes, D. Pillay, J. Shapiro, A. Telenti, and D. Richman. 2004. Update of the drug resistance mutations in HIV-1: 2004. Top. HIV Med. 12:119-124.
15. King, N., M. Prabu-Jeyalaban, P. Wigerinck, M.-P. de Béthune, and C. Schiffer. 2004. The structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease inhibitor. J. Virol. 78:12012-12021.
16. Koh, Y., H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y. F. Wang, Y. Tie, P. Volarath, L. Gaddis, R. W. Harrison, I. T. Weber, A. K. Ghosh, and H. Mitsuya. 2003. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
17. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
18. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick. and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
19. Merrill, D. P., D. J. Manion, T. C. Chou, and M. S. Hirsch. 1997. Antagonism between human immunodeficiency virus type 1 proteasc inhibitors indinavir and saquinavir in vitro. J. Infect. Dis. 176:265-268.
20. Molla, A., H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf. 2002. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. 46:2249-2253.
21. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
22. Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
23. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
24. Perno, C. F., and R. Yarchoan. 1993. Culture of HIV in monocytes and macrophages, p. 12.4.1-12.4.11. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, vol 3. John Wiley & Sons, New York, N.Y.
25. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
26. Robinson, B. S., K. A. Ricrardi, Y. F. Gong, Q. Guo, D. A. Stock, W. S. Blair, B. J. Terry, C. A. Deminie, F. Djang, R. J. Colonno, and P. F. Lin. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099.
27. Swanstrom, R., and J. Erona. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
28. Tie, Y., P. Boross, Y. Wang, L. Gaddis, A. Hussain, S. Leshchenko, A. Ghosh, J. Louis, R. Harrison, and I. Weber. 2004. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug resistant clinical strains. J. Mol. Biol. 338:341-352.
29. Yoshimura, K., R. Kato, M. F. Kavlick, A. Nguyen, V. Maroun, K. Maeda, K. A. Hussain, A. K. Ghosh, S. V. Gulnik, J. W. Erickson, and H. Mitsuya. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.